PDCD1 and cancer: Immunotherapy drugs targeting the programmed cell death protein-1 (PD-1), programmed cell death ligand-1 (PD-L1), or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) block the cancer-derived inhibitory signal on effector T-cells and remove residual cancer cells.